Biomx Inc. (PHGE) — SEC Filings
Biomx Inc. (PHGE) — 50 SEC filings. Latest: 8-K (Apr 16, 2026). Includes 24 8-K, 6 10-Q, 4 SC 13G/A.
Overview
Biomx Inc. (PHGE) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 16, 2026: BiomX Inc. filed an 8-K on April 16, 2026, reporting under Regulation FD and other events. The filing includes a press release dated April 16, 2026, and various XBRL documents. The company's mailing and business address is 850 New Burton Road, Suite 201, Dover, DE 19904.
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 5 bearish, 44 neutral, 1 mixed. The dominant filing sentiment for Biomx Inc. is neutral.
Filing Type Overview
Biomx Inc. (PHGE) has filed 24 8-K, 6 10-Q, 3 DEF 14A, 2 DEFA14A, 1 S-1, 2 10-K, 4 SC 13G/A, 4 SC 13D/A, 2 8-K/A, 1 SC 13G, 1 SC 13D with the SEC between Mar 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of PHGE's 42 recent filings, 5 were flagged as high-risk, 18 as medium-risk, and 19 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | Not explicitly stated |
| Net Income | -$22.862M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $6.923M |
| Operating Margin | N/A |
| Total Assets | $26.168M |
| Total Debt | N/A |
Key Executives
- Hamas
- Hezbollah
- Jonathan Solomon
- Marina Wolfson
- Assad regime
- Carl L. Gordon
- Erez Chimovits
- David Clark
- Flynn James E
Industry Context
BiomX operates in the highly competitive and rapidly evolving biotechnology sector, focusing on phage therapy. This niche area targets specific bacterial infections, offering an alternative to antibiotics. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory hurdles. Key trends include the growing threat of antibiotic resistance, driving demand for novel treatments, and increasing M&A activity as companies seek to bolster their pipelines.
Top Tags
corporate-governance (10) · biotechnology (5) · amendment (5) · biotech (5) · 8-K (4) · filing (4) · Biotechnology (4) · 10-Q (4) · quarterly-report (4) · proxy-statement (4)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $22.862M | Increased from $3.214M net income in 9M 2024, indicating significant financial deterioration. |
| Cash and Cash Equivalents | $6.923M | Decreased from $16.856M at Dec 31, 2024, highlighting rapid cash burn. |
| Operating Loss | $23.725M | For the nine months ended September 30, 2025, compared to $27.838M in 2024. |
| R&D Expenses | $16.386M | For the nine months ended September 30, 2025, down from $18.281M in 2024. |
| Income from Change in Fair Value of Warrants | $1.682M | For the nine months ended September 30, 2025, a significant change from $24.417M income in 2024. |
| Shares Outstanding | 29,006,165 | As of November 11, 2025, indicating potential dilution. |
| Total Stockholders' Equity | $10.486M | Decreased from $24.148M at December 31, 2024, reflecting accumulated losses. |
| Total Current Assets | $8.862M | Decreased from $20.520M at December 31, 2024, signaling reduced liquidity. |
| Minimum reverse stock split ratio | 1-for-5 | Board authorized to amend certificate of incorporation for reverse stock split |
| Maximum reverse stock split ratio | 1-for-20 | Board authorized to amend certificate of incorporation for reverse stock split |
| Date of Annual Meeting | October 16, 2025 | Stockholders will vote on key proposals |
| Record Date for voting | August 22, 2025 | Determines stockholders entitled to vote at the Annual Meeting |
| Common Stock outstanding | 26,554,887 | Total shares entitled to vote as of the Record Date |
| Reverse split implementation deadline | October 16, 2026 | Board has discretion to effect reverse split until this date |
| Number of Class II directors | 3 | To be elected to serve until the 2028 annual meeting |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Biomx Inc. (PHGE)?
Biomx Inc. has 50 recent SEC filings from Mar 2024 to Apr 2026, including 24 8-K, 6 10-Q, 4 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of PHGE filings?
Across 50 filings, the sentiment breakdown is: 5 bearish, 44 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Biomx Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Biomx Inc. (PHGE) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Biomx Inc.?
Key financial highlights from Biomx Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for PHGE?
The investment thesis for PHGE includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Biomx Inc.?
Key executives identified across Biomx Inc.'s filings include Hamas, Hezbollah, Jonathan Solomon, Marina Wolfson, Assad regime and 4 others.
What are the main risk factors for Biomx Inc. stock?
Of PHGE's 42 assessed filings, 5 were flagged high-risk, 18 medium-risk, and 19 low-risk.
What are recent predictions and forward guidance from Biomx Inc.?
Forward guidance and predictions for Biomx Inc. are extracted from SEC filings as they are enriched.